Sun Pharmaceutical Industries announced a drop in consolidated net profit for the quarter ended March 2015, impacted by a few items, relating to professional charges, harmonization of policies of erstwhile Ranbaxy with the company, etc. During the quarter, the profit of the company stood at Rs 8,880.50 million from Rs 15,871.20 million in the same quarter last year.
'In view of the amalgamation with Ranbaxy Laboratories, the figures for the current year and quarter are not comparable with the corresponding figures of the previous year's quarter,' the company said.
Revenues for the quarter stood at Rs 65,407.40 million, compared with Rs 42,524 million for the prior year period.
Dilip Shanghvi, Managing Director of the Company said, 'Post the completion of the merger, we have commenced the integration of Ranbaxy. Our performance has been impacted due to various one-time charges, mainly on account of the Ranbaxy merger as well as due to price erosion for some of our products in the US. It also reflects the impact of supply constraints related to the on-going remediation efforts at some of our facilities. We are pledged to being 100% cGMP compliant and are fully responsible towards our customers and patients across the world who rely on us for quality products.'
| Quarterly Results - Consolidated (Rs in mn) |
| As at | Mar - 15 | Mar - 14 | %Change |
| Revenues | 65,407.40 | 42,524.40 | 53.81 |
| Net Profit | 8,880.50 | 15,871.20 | (44.05) |
| Diluted EPS | NA | NA | |
Shares of the company gained Rs 10, or 1.05%, to settle at Rs 965.75. The total volume of shares traded was 406,879 at the BSE (Friday).
